0 98

Cited 0 times in

Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이재승-
dc.contributor.author이혜원-
dc.contributor.author전호수-
dc.date.accessioned2022-08-23T00:12:49Z-
dc.date.available2022-08-23T00:12:49Z-
dc.date.issued2022-04-
dc.identifier.issn1542-3565-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189315-
dc.description.abstractBackground & aims: Cirrhosis and age (CAGE-B) and stiffness and age (SAGE-B) models assess the risk of hepatocellular carcinoma (HCC) development in white patients with chronic hepatitis B (CHB) undergoing sustained antiviral therapy (AVT). Herein, we checked the predictive performance of these models in Asian patients with CHB. Methods: We reviewed 734 treatment-naive patients with CHB who started entecavir between 2006 and 2011 and were followed up for more than 5 years without HCC development during AVT. The predictive performance of CAGE-B and SAGE-B models was calculated using area under the receiver operating characteristic curves (AUROCs). Results: Median liver stiffness assessed using transient elastography after 5 years of AVT was 6.8 kPa. Median CAGE-B and SAGE-B models after 5 years of AVT were 7.0 and 6.0, respectively. More than 5 years after AVT initiation, 66 patients (9.0%) developed HCC. The AUROCs of the CAGE-B and SAGE-B models were 0.764 and 0.785 after 7 years and 0.799 and 0.802 after 10 years of AVT, respectively. The cumulative incidence of HCC was significantly higher in the high-risk groups according to CAGE-B and SAGE-B risk stratification than in the medium- and low-risk groups (P < .05 in all cases). The SAGE-B model showed a higher likelihood ratio (χ2) (76.2 vs 71.4) and linear trend (χ2) (74.1 vs 58.6) than the CAGE-B model, whereas the CAGE-B model showed higher Akaike information criteria (64.3 vs 50.3). Conclusions: Both SAGE-B and CAGE-B showed acceptable performance in predicting HCC after 5 years of AVT in Asian patients with CHB.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherW.B. Saunders-
dc.relation.isPartOfCLINICAL GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents / therapeutic use-
dc.subject.MESHCarcinoma, Hepatocellular* / etiology-
dc.subject.MESHGuanine / analogs & derivatives-
dc.subject.MESHHepatitis B, Chronic* / complications-
dc.subject.MESHHepatitis B, Chronic* / drug therapy-
dc.subject.MESHHepatitis B, Chronic* / pathology-
dc.subject.MESHHumans-
dc.subject.MESHLiver Cirrhosis / complications-
dc.subject.MESHLiver Neoplasms* / etiology-
dc.titlePredictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHye Yeon Chon-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorHo Soo Chun-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorWon Young Tak-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorYoung-Oh Kweon-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorSe Young Jang-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.1016/j.cgh.2021.06.001-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA05963-
dc.contributor.localIdA03318-
dc.contributor.localIdA05908-
dc.relation.journalcodeJ02981-
dc.identifier.eissn1542-7714-
dc.identifier.pmid34091048-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1542356521006042?via%3Dihub-
dc.subject.keywordCAGE-B-
dc.subject.keywordChronic Hepatitis B-
dc.subject.keywordHepatocellular Carcinoma-
dc.subject.keywordRisk Prediction Model-
dc.subject.keywordSAGE-B-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이재승-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor전호수-
dc.citation.volume20-
dc.citation.number4-
dc.citation.startPagee794-
dc.citation.endPagee807-
dc.identifier.bibliographicCitationCLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.20(4) : e794-e807, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.